32.17
price up icon6.98%   2.10
after-market アフターアワーズ: 32.17
loading
前日終値:
$30.07
開ける:
$31.37
24時間の取引高:
658.24K
Relative Volume:
0.91
時価総額:
$2.19B
収益:
$87.56M
当期純損益:
$-167.47M
株価収益率:
-13.75
EPS:
-2.34
ネットキャッシュフロー:
$-148.20M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
+33.37%
6か月 パフォーマンス:
-35.66%
1年 パフォーマンス:
-15.12%
1日の値動き範囲:
Value
$30.51
$33.71
1週間の範囲:
Value
$28.28
$33.71
52週間の値動き範囲:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1154)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
188
Name
Twitter
Name
次回の収益日
2025-02-21
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

KYMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
32.17 2.19B 87.56M -167.47M -148.20M -2.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
439.37 128.45B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
575.63 65.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
560.90 40.09B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.19 35.67B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
233.25 27.44B 3.81B -644.79M -669.77M -6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
May 12, 2025

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from Guggenheim | KYMR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025
pulisher
May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025
pulisher
May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases - Investing.com

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World

May 10, 2025
pulisher
May 10, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India

May 10, 2025
pulisher
May 10, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com

May 10, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa

May 09, 2025
pulisher
May 09, 2025

Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Strong Q1 Performance | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Introduces KT-579 Targeting IRF5 - TipRanks

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Advances Oral Immunology Pipeline with Promising New Program Targeting IRF5 for Autoimmune Diseases - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire Inc.

May 09, 2025
pulisher
May 08, 2025

What's Next: Kymera Therapeutics's Earnings Preview - Nasdaq

May 08, 2025
pulisher
May 08, 2025

What To Expect From Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Dimensional Fund Advisors LP Sells 38,871 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 08, 2025
pulisher
May 07, 2025

KYMERA THERAPEUTICS Earnings Preview: Recent $KYMR Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Friday - Defense World

May 07, 2025
pulisher
May 06, 2025

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $56.36 - Defense World

May 06, 2025
pulisher
May 02, 2025

Kymera Therapeutics Inc’s results are impressive - uspostnews.com

May 02, 2025
pulisher
May 02, 2025

Market Momentum Report: Kymera Therapeutics Inc (KYMR)’s Positive Close at 34.55 - DWinneX

May 02, 2025
pulisher
May 01, 2025

Invesco Ltd. Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 01, 2025
pulisher
May 01, 2025

Wells Fargo & Company MN Acquires 7,487 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 01, 2025

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.75
price up icon 4.10%
$19.93
price up icon 2.94%
$33.35
price up icon 0.60%
$25.26
price up icon 5.43%
$97.27
price up icon 4.85%
biotechnology ONC
$233.25
price up icon 0.54%
大文字化:     |  ボリューム (24 時間):